Anlon Healthcare DuPont analysis

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
0.68×
0.92×
26.7%
0.46×
1.47×
11.4%
12.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AHCL₹25.11

Anlon Healthcare Limited

· Pharma & Health
₹ CrorePeersANUHPHRWANBURYBAJAJHCAREZIMLABTHEMISMEDLINCOLNSIGACHIVALIANTLABMcap ₹133 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY26
31/03/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.68
Interest Burden (Pretax/EBIT) ×0.92
EBIT Margin %26.75
Asset Turnover ×0.46
Financial Leverage (Assets/Equity) ×1.47
ROE (5-step product, year-end total equity) %11.42
ROE (owners' profit / average owners' equity) %12.38
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.